While MDSCs of late stage of experimental Sjögren’s syndrome (10 weeks postimmunization) expressed markers of more differentiated mature phenotype (high expression levels of CD40, CD80, CD86 and MHC-II markers), drastic reduction of suppressive activity and decreased arginase activity and NO levels. This evidence concerns the gene CD86 and Sjogren syndrome.